Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8605 |
High Similarity |
NPD6651 |
Approved |
0.8333 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.8248 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.8188 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8168 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8168 |
Intermediate Similarity |
NPD943 |
Approved |
0.8058 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8045 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7956 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7926 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.781 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.781 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7754 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7724 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7687 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7634 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7619 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7609 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7609 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7609 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7609 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7597 |
Intermediate Similarity |
NPD1201 |
Approved |
0.7584 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7552 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7552 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7552 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7551 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.75 |
Intermediate Similarity |
NPD1470 |
Approved |
0.7482 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7482 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7434 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7383 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7376 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7361 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7361 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7315 |
Intermediate Similarity |
NPD1934 |
Approved |
0.729 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7267 |
Intermediate Similarity |
NPD2801 |
Approved |
0.726 |
Intermediate Similarity |
NPD1512 |
Approved |
0.725 |
Intermediate Similarity |
NPD846 |
Approved |
0.725 |
Intermediate Similarity |
NPD940 |
Approved |
0.7244 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7237 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7203 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7203 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7192 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7181 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7177 |
Intermediate Similarity |
NPD74 |
Approved |
0.7177 |
Intermediate Similarity |
NPD9266 |
Approved |
0.7171 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7171 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7163 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7153 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7152 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7132 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7101 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD9267 |
Approved |
0.7097 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD9263 |
Approved |
0.7097 |
Intermediate Similarity |
NPD9264 |
Approved |
0.707 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.707 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.707 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7063 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7044 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7034 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7015 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7013 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6985 |
Remote Similarity |
NPD1203 |
Approved |
0.698 |
Remote Similarity |
NPD920 |
Approved |
0.6978 |
Remote Similarity |
NPD2313 |
Discontinued |
0.697 |
Remote Similarity |
NPD9268 |
Approved |
0.6966 |
Remote Similarity |
NPD2654 |
Approved |
0.6943 |
Remote Similarity |
NPD5711 |
Approved |
0.6943 |
Remote Similarity |
NPD5710 |
Approved |
0.6934 |
Remote Similarity |
NPD2798 |
Approved |
0.6894 |
Remote Similarity |
NPD9545 |
Approved |
0.6894 |
Remote Similarity |
NPD7074 |
Phase 3 |
0.6875 |
Remote Similarity |
NPD3818 |
Discontinued |
0.6871 |
Remote Similarity |
NPD2309 |
Approved |
0.6871 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD5403 |
Approved |
0.685 |
Remote Similarity |
NPD4750 |
Phase 3 |
0.6846 |
Remote Similarity |
NPD9281 |
Approved |
0.6839 |
Remote Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6833 |
Remote Similarity |
NPD2859 |
Approved |
0.6833 |
Remote Similarity |
NPD2860 |
Approved |
0.6832 |
Remote Similarity |
NPD6020 |
Phase 2 |
0.6832 |
Remote Similarity |
NPD7054 |
Approved |
0.6831 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6824 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD5494 |
Approved |
0.681 |
Remote Similarity |
NPD6559 |
Discontinued |
0.6806 |
Remote Similarity |
NPD3748 |
Approved |
0.679 |
Remote Similarity |
NPD7472 |
Approved |
0.6776 |
Remote Similarity |
NPD3226 |
Approved |
0.6774 |
Remote Similarity |
NPD9261 |
Approved |
0.6765 |
Remote Similarity |
NPD9717 |
Approved |
0.6765 |
Remote Similarity |
NPD3972 |
Approved |
0.6759 |
Remote Similarity |
NPD6099 |
Approved |
0.6759 |
Remote Similarity |
NPD6100 |
Approved |
0.675 |
Remote Similarity |
NPD2934 |
Approved |
0.675 |
Remote Similarity |
NPD2933 |
Approved |
0.6748 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6748 |
Remote Similarity |
NPD1242 |
Phase 1 |
0.6738 |
Remote Similarity |
NPD3268 |
Approved |
0.6738 |
Remote Similarity |
NPD3764 |
Approved |
0.6733 |
Remote Similarity |
NPD5401 |
Approved |
0.6733 |
Remote Similarity |
NPD642 |
Clinical (unspecified phase) |
0.6712 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6711 |
Remote Similarity |
NPD3300 |
Phase 2 |
0.6707 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6694 |
Remote Similarity |
NPD1809 |
Phase 2 |
0.6689 |
Remote Similarity |
NPD3400 |
Discontinued |
0.6667 |
Remote Similarity |
NPD8438 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD2932 |
Approved |
0.6667 |
Remote Similarity |
NPD3019 |
Approved |
0.6667 |
Remote Similarity |
NPD3020 |
Approved |
0.6667 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6645 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6641 |
Remote Similarity |
NPD6831 |
Clinical (unspecified phase) |
0.662 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6619 |
Remote Similarity |
NPD2797 |
Approved |
0.6603 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6597 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6597 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6587 |
Remote Similarity |
NPD1237 |
Approved |
0.6585 |
Remote Similarity |
NPD1729 |
Discontinued |
0.6584 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6577 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6577 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6569 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6569 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6566 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6561 |
Remote Similarity |
NPD5402 |
Approved |
0.6558 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6541 |
Remote Similarity |
NPD919 |
Approved |
0.6529 |
Remote Similarity |
NPD845 |
Approved |
0.6524 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6508 |
Remote Similarity |
NPD1929 |
Approved |
0.6508 |
Remote Similarity |
NPD1930 |
Approved |
0.6508 |
Remote Similarity |
NPD1931 |
Clinical (unspecified phase) |
0.6494 |
Remote Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.6479 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6474 |
Remote Similarity |
NPD4363 |
Phase 3 |
0.6474 |
Remote Similarity |
NPD4360 |
Phase 2 |
0.6467 |
Remote Similarity |
NPD7003 |
Approved |
0.6466 |
Remote Similarity |
NPD5951 |
Approved |
0.6463 |
Remote Similarity |
NPD3299 |
Clinical (unspecified phase) |
0.6463 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6463 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.646 |
Remote Similarity |
NPD1247 |
Approved |
0.6458 |
Remote Similarity |
NPD520 |
Approved |
0.6446 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6437 |
Remote Similarity |
NPD4362 |
Clinical (unspecified phase) |
0.6437 |
Remote Similarity |
NPD4361 |
Phase 2 |
0.6406 |
Remote Similarity |
NPD5048 |
Discontinued |
0.6397 |
Remote Similarity |
NPD1548 |
Phase 1 |
0.6384 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6383 |
Remote Similarity |
NPD3267 |
Approved |
0.6383 |
Remote Similarity |
NPD3266 |
Approved |
0.6369 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6364 |
Remote Similarity |
NPD6124 |
Clinical (unspecified phase) |
0.6364 |
Remote Similarity |
NPD5049 |
Phase 3 |
0.6358 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6352 |
Remote Similarity |
NPD2296 |
Approved |
0.6338 |
Remote Similarity |
NPD6007 |
Clinical (unspecified phase) |
0.6336 |
Remote Similarity |
NPD3021 |
Approved |
0.6336 |
Remote Similarity |
NPD3022 |
Approved |
0.6331 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6319 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6316 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6316 |
Remote Similarity |
NPD7635 |
Approved |
0.6316 |
Remote Similarity |
NPD6190 |
Approved |
0.6312 |
Remote Similarity |
NPD1876 |
Approved |
0.6312 |
Remote Similarity |
NPD3225 |
Approved |
0.631 |
Remote Similarity |
NPD6104 |
Discontinued |
0.6306 |
Remote Similarity |
NPD6585 |
Discontinued |
0.6294 |
Remote Similarity |
NPD4208 |
Discontinued |
0.6286 |
Remote Similarity |
NPD1608 |
Approved |
0.6286 |
Remote Similarity |
NPD6535 |
Approved |
0.6286 |
Remote Similarity |
NPD6534 |
Approved |
0.6277 |
Remote Similarity |
NPD1759 |
Phase 1 |
0.6276 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6276 |
Remote Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.6276 |
Remote Similarity |
NPD411 |
Approved |
0.6269 |
Remote Similarity |
NPD7159 |
Clinical (unspecified phase) |
0.6267 |
Remote Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.6267 |
Remote Similarity |
NPD1471 |
Phase 3 |
0.6266
|
Remote Similarity |
NPD5889 |
Approved |